Open AccessFrailty, Mycophenolate Reduction, and Graft Loss in Kidney Transplant Recipients
Author(s) -
Mara McAdamsDeMarco,
Amanda J. Law,
Jingwen Tan,
C. Delp,
Elizabeth A. King,
Babak J. Orandi,
Megan L. Salter,
Nada Alachkar,
Niraj M. Desai,
Morgan E. Grams,
Jeremy Walston,
Dorry L. Segev
Publication year - 2015
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000000444
Subject(s) - medicine , hazard ratio , discontinuation , mycophenolic acid , immunosuppression , kidney transplantation , proportional hazards model , transplantation , confidence interval , incidence (geometry) , urology , gastroenterology , surgery , physics , optics
Mycophenolate mofetil (MMF) side effects often prompt dose reduction or discontinuation, and this MMF dose reduction (MDR) can lead to rejection and possibly graft loss. Unfortunately, little is known about what factors might cause or contribute to MDR. Frailty, a measure of physiologic reserve, is emerging as an important, novel domain of risk in kidney transplantation recipients. We hypothesized that frailty, an inflammatory phenotype, might be associated with MDR.